ResMed Inc.
RMD · NYSE
Analyst Consensus
Hold
Analyst Ratings Synthesis
The consensus rating is Hold, supported by 14 analysts, with a mean price target of $231. The supplied consensus has no low or high target, so target clustering and the width of the spread cannot be established. It also does not identify the most bullish or least bullish analyst. No named analyst revisions were supplied for the past week, preventing a conclusion about whether targets moved higher or lower. The substantive disagreement visible in the research is instead about near-term earnings execution: one Zacks preview cites strong demand and 13.7% expected EPS growth, while another says ResMed lacks the ingredients for a likely beat. No firm-specific rating action is attributable from the evidence.
- Why ResMed (RMD) is a Top Growth Stock for the Long-Term
- Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates
- Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
- ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
- Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates
Rating Actions
No individual rating actions have been captured for RMDyet. Consensus figures above come from Nasdaq's aggregate feed.
